Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Esplugues De Llobregat

3 740 clinical trials in Esplugues De Llobregat, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Esplugues De Llobregat at a glance
3 740
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 740 trials in Esplugues De Llobregat

Open in trial search

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Vaccines US Inc.

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Obesity+1

Recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Vaccines US Inc.

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LU AF28996 DH1
  • Sponsor:H. Lundbeck A/S

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Esplugues De Llobregat

What the registry says about research in the country

01 Pediatric Oncology Research

Innovative clinical trials focusing on pediatric cancers include studies for neuroblastoma, hepatic tumors, and various sarcomas. Research efforts target both primary and refractory disease states.

  • High-risk neuroblastoma treatments
  • Hepatoblastoma and hepatocellular carcinoma therapies
  • Ewing sarcoma management

Studies are evaluating novel therapeutic approaches for improving patient outcomes in challenging pediatric cancers.

02 Rare Genetic Disorders

Research initiatives addressing rare genetic conditions are exploring new treatment options for conditions affecting children and young adults.

  • Duchenne Muscular Dystrophy
  • Angelman Syndrome
  • Prader-Willi Syndrome
  • Hunter Syndrome

These trials aim to evaluate innovative therapies targeting specific genetic mechanisms.

03 Respiratory and Immunological Studies

Clinical research focusing on respiratory conditions and immunological responses, particularly in pediatric populations.

  • RSV prevention in high-risk infants
  • Allergic rhinitis treatments
  • Bronchopulmonary dysplasia management

Studies emphasize both preventive measures and therapeutic interventions for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.